Lisocabtagene maraleucel CAR-T cells - second line treatment in patients with relapsed or refractory large B cell lymphoma
Bull Cancer. 2023 Sep 1:S0007-4551(23)00334-X. doi: 10.1016/j.bulcan.2023.06.010. Online ahead of print.NO ABSTRACTPMID:37661551 | DOI:10.1016/j.bulcan.2023.06.010 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - September 4, 2023 Category: Cancer & Oncology Authors: Mathilde Chanut Charles Herbaux Source Type: research
Digital twins in cancer research and treatment: A future for personalized medicine
Bull Cancer. 2023 Sep 1:S0007-4551(23)00343-0. doi: 10.1016/j.bulcan.2023.07.007. Online ahead of print.NO ABSTRACTPMID:37661550 | DOI:10.1016/j.bulcan.2023.07.007 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - September 4, 2023 Category: Cancer & Oncology Authors: Pierre Etienne Heudel Felix Renard Arnaud Attye Source Type: research
Lisocabtagene maraleucel CAR-T cells - second line treatment in patients with relapsed or refractory large B cell lymphoma
Bull Cancer. 2023 Sep 1:S0007-4551(23)00334-X. doi: 10.1016/j.bulcan.2023.06.010. Online ahead of print.NO ABSTRACTPMID:37661551 | DOI:10.1016/j.bulcan.2023.06.010 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - September 4, 2023 Category: Cancer & Oncology Authors: Mathilde Chanut Charles Herbaux Source Type: research
Digital twins in cancer research and treatment: A future for personalized medicine
Bull Cancer. 2023 Sep 1:S0007-4551(23)00343-0. doi: 10.1016/j.bulcan.2023.07.007. Online ahead of print.NO ABSTRACTPMID:37661550 | DOI:10.1016/j.bulcan.2023.07.007 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - September 4, 2023 Category: Cancer & Oncology Authors: Pierre Etienne Heudel Felix Renard Arnaud Attye Source Type: research
Lisocabtagene maraleucel CAR-T cells - second line treatment in patients with relapsed or refractory large B cell lymphoma
Bull Cancer. 2023 Sep 1:S0007-4551(23)00334-X. doi: 10.1016/j.bulcan.2023.06.010. Online ahead of print.NO ABSTRACTPMID:37661551 | DOI:10.1016/j.bulcan.2023.06.010 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - September 4, 2023 Category: Cancer & Oncology Authors: Mathilde Chanut Charles Herbaux Source Type: research
Digital twins in cancer research and treatment: A future for personalized medicine
Bull Cancer. 2023 Sep 1:S0007-4551(23)00343-0. doi: 10.1016/j.bulcan.2023.07.007. Online ahead of print.NO ABSTRACTPMID:37661550 | DOI:10.1016/j.bulcan.2023.07.007 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - September 4, 2023 Category: Cancer & Oncology Authors: Pierre Etienne Heudel Felix Renard Arnaud Attye Source Type: research
Lisocabtagene maraleucel CAR-T cells - second line treatment in patients with relapsed or refractory large B cell lymphoma
Bull Cancer. 2023 Sep 1:S0007-4551(23)00334-X. doi: 10.1016/j.bulcan.2023.06.010. Online ahead of print.NO ABSTRACTPMID:37661551 | DOI:10.1016/j.bulcan.2023.06.010 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - September 4, 2023 Category: Cancer & Oncology Authors: Mathilde Chanut Charles Herbaux Source Type: research
Real-world dostarlimab use in advanced/recurrent endometrial cancer in France
DISCUSSION: The enrolment of 80 patients in an 8-month period highlights the need for access to novel treatment regimens in France for these patients post-platinum. Prospective randomized studies are ongoing to assess the efficacy and safety of dostarlimab and other checkpoint inhibitors as first-line treatment in patients with endometrial cancer.PMID:37659907 | DOI:10.1016/j.bulcan.2023.06.009 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - September 2, 2023 Category: Cancer & Oncology Authors: Manuel Rodrigues Lauriane Eberst Philippe Follana Ludiane Gauthier Virginie Jacquemin Christophe Tessier Nadia El Mouaddin Philippe Boudier Frederic Fiteni Eurydice Angeli Sophie Roche Nicolas Delanoy Renaud Sabatier Ronan Flippot Thibault de la Motte Rou Source Type: research
Pirtobrutinib in Covalent BTK-Inhibitor pre-treated relapsed/refractory (R/R) Mantle Cell Lymphoma
Bull Cancer. 2023 Aug 30:S0007-4551(23)00336-3. doi: 10.1016/j.bulcan.2023.07.002. Online ahead of print.NO ABSTRACTPMID:37658026 | DOI:10.1016/j.bulcan.2023.07.002 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - September 1, 2023 Category: Cancer & Oncology Authors: Caroline Fileni Cl émentine Sarkozy Source Type: research
Pirtobrutinib in Covalent BTK-Inhibitor pre-treated relapsed/refractory (R/R) Mantle Cell Lymphoma
Bull Cancer. 2023 Aug 30:S0007-4551(23)00336-3. doi: 10.1016/j.bulcan.2023.07.002. Online ahead of print.NO ABSTRACTPMID:37658026 | DOI:10.1016/j.bulcan.2023.07.002 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - September 1, 2023 Category: Cancer & Oncology Authors: Caroline Fileni Cl émentine Sarkozy Source Type: research
Recommandations pour la pratique clinique Nice/Saint-Paul-de-Vence 2022 –2023 : Diagnostic histomoléculaire des carcinomes de l'endomètre
Bull Cancer. 2023 Jun;110(6S):6S10-6S19. doi: 10.1016/S0007-4551(23)00330-2.ABSTRACTFrench recommendations for clinical practice Nice-Saint-Paul de Vence 2022-2023: histomolecular diagnosis of endometrial carcinomas The characterisation of endometrial carcinomas has been recently modified and enriched by molecular classification, the integration of which now impacts therapeutic decisions on whether adjuvant therapy should be administered or not in localized tumors, and influences treatment selection in advanced disease. Mandatory information includes histological type according to WHO 2020 classification, histological grad...
Source: Bulletin du Cancer - August 12, 2023 Category: Cancer & Oncology Authors: Corinne Jeanne Isabelle Treilleux Marie-Aude Le Fr ère-Belda J érôme Alexandre Florence Joly Etienne Rouleau Source Type: research
Recommandations pour la pratique clinique Nice/Saint-Paul-de-Vence 2022 –2023 : prise en charge du cancer de l'endomètre localisé
Bull Cancer. 2023 Jun;110(6S):6S20-6S33. doi: 10.1016/S0007-4551(23)00331-4.ABSTRACTRecommendations for clinical practice, Nice/Saint-Paul-de-Vence 2022-2023: Management of localized endometrial cancer Endometrial cancer is the most frequent gynecological cancers in industrialized countries and its incidence increases. The newmolecularclassification allows determination of the risk of recurrence and helps orienting therapeutic management. Surgery remains the cornerstone of treatment. Minimally invasive approach must be preferred for stages I and II. Surgery includes hysterectomy with bilateral adnexectomy, sentinel lymph n...
Source: Bulletin du Cancer - August 12, 2023 Category: Cancer & Oncology Authors: Alejandra Mart ínez Cyrus Chargari Elsa Kalbacher Anne-Lise Gaillard Alexandra Leary Martin Koskas Nicol ás Chopin Anne-Agathe Serre Anne-Claire Hardy-Bessard Ch érif Akladios Fabrice Lecuru Source Type: research
Recommandations pour la pratique clinique Nice/Saint-Paul-de-Vence 2022 –2023 : Prise en charge du cancer de l'endomètre métastatique et/ou en rechute
Bull Cancer. 2023 Jun;110(6S):6S34-6S43. doi: 10.1016/S0007-4551(23)00332-6.ABSTRACTRecommendations for clinical practice Nice/Saint-Paul-de-Vence 2022-2023 : Management of advanced/relapsing endometrial cancer Since the first recommendations in 2020 concerning metastatic and/or relapsed endometrial cancer, new treatment options have shown a benefit on patients' life expectancy, justifying their update. In first line, the choice will be made between chemotherapy with carboplatin/paclitaxel or hormone therapy with progestin, depending on tumor characteristics (histological type, grade, expression of hormone receptors, rate ...
Source: Bulletin du Cancer - August 12, 2023 Category: Cancer & Oncology Authors: J érôme Alexandre Marie-Aude Le Fr ère-Belda Antoine Angelergues Gwena ël Ferron Isabelle Treilleux Anne-Lise Gaillard Jean-S ébastien Frenel Beno ît You Etienne Rouleau Alain Lortholary Isabelle Ray-Coquard Florence Joly Pour le groupe GINECO Source Type: research
Recommandations pour la pratique clinique Nice/Saint-Paul-de-Vence 2022 –2023 : Prise en charge du cancer du col de l'utérus avancé
Bull Cancer. 2023 Jun;110(6S):6S44-6S50. doi: 10.1016/S0007-4551(23)00333-8.ABSTRACTFrench recommendations for clinical practice, Nice/Saint-Paul-de-Vence 2022-2023: Management of advanced cervical cancer The prognosis of cervical cancer remained pejorative until recently, first-line treatment consisting of platinum-based chemotherapy, associated with bevacizumab whenever possible, without any other therapeutic innovation for several years. However in 2022, immunotherapy appeared in the therapeutic landscape. Pembrolizumab can now be prescribed, thanks to the early access status granted by the HAS in September 2022, in pat...
Source: Bulletin du Cancer - August 12, 2023 Category: Cancer & Oncology Authors: Patricia Pautier Catherine Genestie Laurence Gladieff Jean-Emmanuel Kurtz Alain Lortholary Thibault de La Motte Rouge Anne-Lise Gaillard Anne Ducassou Coraline Dubot Etienne Rouleau Fabrice Narducci Sylvain Demontoy Christophe Hennequin Source Type: research
Prise en charge des carcinomes ovariens de haut grade s éreux et/ou endométrioïdes de stades avancés (III-IV) et testing HRD-BRCA en 2023 : actualisation selon les données publiées et/ou présentées en 2022
Bull Cancer. 2023 Jun;110(6S):6S5-6S9. doi: 10.1016/S0007-4551(23)00329-6.ABSTRACTManagement of high grade, serous and/or endometrioid, advanced (stages III-IV) ovarian carcinomas and HRD-BRCA testing in 2023: update according to data published/presented in 2022 Molecular analysis of ovarian carcinomas must be now systematically performed to determine BRCA1 and BRCA2 status as well as genomic instability score. Several types of tests are available. From a clinical perspective, new data from phase III clinical trials presented in 2022 confirm the key role of PARP inhibitors in first-line medical treatment of high-grade sero...
Source: Bulletin du Cancer - August 12, 2023 Category: Cancer & Oncology Authors: Fr édéric Selle Florence Joly Laurence Gladieff Karine Prulhi ère Alexandra Leary Elsa Kalbacher Etienne Rouleau Isabelle Ray-Coquard Source Type: research
